Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and plx 4720

sorafenib has been researched along with plx 4720 in 13 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(plx 4720)		Trials
(plx 4720)		Recent Studies (post-2010) (plx 4720)
6,5207305,2511631151

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)plx 4720 (IC50)
Chain A, B-Raf proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.16
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1Homo sapiens (human)0.16
Chain A, Basic fibroblast growth factor receptor 1Homo sapiens (human)0.16
PirinHomo sapiens (human)0.67
Aurora kinase AHomo sapiens (human)1.8466
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)1.8466
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.0065
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)1.8466
Fibroblast growth factor receptor 1Homo sapiens (human)1.8466
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)1.3575
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.8593
Vascular endothelial growth factor receptor 2Homo sapiens (human)1.3575
Tyrosine-protein kinase CSKHomo sapiens (human)1.8466
Tyrosine-protein kinase FRKHomo sapiens (human)1.3575
Focal adhesion kinase 1Homo sapiens (human)1.8466
Protein-tyrosine kinase 6Homo sapiens (human)1.3575

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's10 (76.92)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Kim, J; Wang, X1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Agianian, B; Gavathiotis, E1
Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Mersal, KI; Oh, CH; Yoo, KH1
Amaravadi, R; Fecher, LA; Schuchter, LM1
Fliegel, L; Karki, P; Li, X; Schrama, D1
Bollag, G1
Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J1
Braun, S; Brummer, T; Capper, D; Eisenhardt, AE; Fiala, GJ; Halbach, S; Heilmann, K; Herr, R; Röring, M; Saunders, DN; Schamel, WW; von Deimling, A1
Ahn, SK; Eum, KH; Kang, H; Lee, M1
Bühler, A; Döhner, H; Jebaraj, BM; Kienle, D; Stilgenbauer, S; Winkler, D; Zenz, T1
Brors, B; Haibe-Kains, B; Kurilov, R1

Reviews

1 review(s) available for sorafenib and plx 4720

ArticleYear
Current Insights of BRAF Inhibitors in Cancer.
    Journal of medicinal chemistry, 2018, 07-26, Volume: 61, Issue:14

    Topics: Animals; Drug Discovery; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf

2018

Other Studies

12 other study(ies) available for sorafenib and plx 4720

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Conformation-specific effects of Raf kinase inhibitors.
    Journal of medicinal chemistry, 2012, Sep-13, Volume: 55, Issue:17

    Topics: Dimerization; Models, Molecular; Protein Conformation; Protein Kinase Inhibitors; raf Kinases

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
    Bioorganic & medicinal chemistry, 2020, 06-01, Volume: 28, Issue:11

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrroles; Structure-Activity Relationship

2020
Effectively targeting BRAF in melanoma: a formidable challenge.
    Pigment cell & melanoma research, 2008, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Treatment Outcome

2008
B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
    The Journal of biological chemistry, 2011, Apr-15, Volume: 286, Issue:15

    Topics: Amino Acid Substitution; Animals; Benzenesulfonates; Cation Transport Proteins; Cell Movement; Cell Size; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indoles; Melanoma; Mutation, Missense; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyridines; Rabbits; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfonamides

2011
Setting up a kinase discovery and development project.
    Current topics in microbiology and immunology, 2012, Volume: 355

    Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Enzyme Assays; Humans; Indoles; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Solubility; Sorafenib; Structure-Activity Relationship; Sulfonamides

2012
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-15, Volume: 17, Issue:22

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glutamic Acid; Indoles; Melanoma; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2011
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.
    The EMBO journal, 2012, May-30, Volume: 31, Issue:11

    Topics: Benzenesulfonates; Caco-2 Cells; HCT116 Cells; HT29 Cells; Humans; Indoles; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides

2012
Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
    Molecular and cellular biochemistry, 2013, Volume: 372, Issue:1-2

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Caspase 3; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases

2013
BRAF mutations in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Exons; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Sorafenib; Sulfonamides; Treatment Outcome

2013
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
    Scientific reports, 2020, 02-18, Volume: 10, Issue:1

    Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2020